3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
147
Melanoma
122
Breast Neoplasms
98
Squamous Cell Carcinoma of Head and Neck
96
Triple Negative Breast Neoplasms
85
Lung Neoplasms
64
Neoplasm Metastasis
53
Carcinoma, Renal Cell
49
Neoplasms
46
Head and Neck Neoplasms
46
Colorectal Neoplasms
41
Ovarian Neoplasms
38
Carcinoma, Transitional Cell
36
Carcinoma, Hepatocellular
36
Pancreatic Neoplasms
35
Urinary Bladder Neoplasms
34
Recurrence
33
Stomach Neoplasms
32
Glioblastoma
30
Brain Neoplasms
28
Sarcoma
26
Endometrial Neoplasms
25
Prostatic Neoplasms
23
Hodgkin Disease
22
Uterine Cervical Neoplasms
19
Fallopian Tube Neoplasms
19
Carcinoma, Squamous Cell
19
Esophageal Squamous Cell Carcinoma
17
Adenocarcinoma
17
Multiple Myeloma
16
Interventions
lutetium Lu 177 dotatate
5
copper dotatate CU-64
3
Magnetic Resonance Spectroscopy
3
lanreotide
2
gallium Ga 68 dotatate
2
Nivolumab
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Carboplatin
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
pasireotide
1
irinotecan sucrosofate
1
folfirinox
1
cabozantinib
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Somatostatin
1
Resveratrol
1
Radiosurgery
1
Octreotide
1
Ipilimumab
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastro-enteropancreatic neuroendocrine tumor
×
pembrolizumab
×
Clear all
NCT03043664
2023-06-29
PLANET
Duke University
Phase 1/2
Completed
22 enrolled
12 charts